ANNEXON INC. - COMMON STOCK

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

21 Oct 2024 19:00:41 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in Upcoming September Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

12 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

16 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

11 Jul 2024 17:09:09 By Nasdaq GlobeNewswire

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

25 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

17 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Annexon Announces Pricing of $125 Million Underwritten Public Offering

05 Jun 2024 22:04:27 By Nasdaq GlobeNewswire

Annexon Announces Proposed Public Offering of Common Stock

04 Jun 2024 16:06:35 By Nasdaq GlobeNewswire

Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

04 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

03 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 May 2024 15:05:00 By Nasdaq GlobeNewswire